Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Vincerx Pharma Inc (VINC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vincerx Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.8368 -0.0403    -4.59%
05:56:25 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 345,147
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.7951 - 0.8900
Type:  Equity
Market:  United States
Vincerx Pharma 0.8368 -0.0403 -4.59%

Vincerx Pharma Inc Company Profile

 
Get an in-depth profile of Vincerx Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

42

Equity Type

ORD

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.

Contact Information

Address 260 Sheridan Avenue Suite 400
Palo Alto, 94306
United States
Phone 650 800 6676
Fax -

Top Executives

Name Age Since Title
Laura I. Bushnell 54 2020 Independent Director
Francisco D. Salva 52 2020 Independent Director
Howard A. Burris - 2021 Member of Scientific Advisory Board
Brian J. Druker 67 2020 Independent Director
John H. Lee 55 2020 Independent Director
John C. Byrd - 2021 Founder & Chairman of Scientific Advisory Board
Anthony W. Tolcher - 2021 Member of Scientific Advisory Board
Ruth E. Stevens 64 2021 Independent Director
Andre Goy - 2021 Member of Scientific Advisory Board
Apostolia Tsimberidou - 2024 Member of Scientific Advisory Board
Naval G. Daver - 2024 Member of Scientific Advisory Board
Ian W. Flinn - 2021 Member of Scientific Advisory Board
Alice Mims - 2024 Member of Scientific Advisory Board
Marina Konopleva - 2024 Member of Scientific Advisory Board
Uma Borate - 2024 Member of Scientific Advisory Board
Amer Zeidan - 2024 Member of Scientific Advisory Board
Raquel E. Izumi 54 2020 Co-Founder, President, COO, Secretary & Director
Ahmed M. Hamdy 59 2020 Co-Founder, Chairman & CEO
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VINC Comments

Write your thoughts about Vincerx Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email